Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: Disclosed are effective fixed dose oral testosterone undecanoate compositions for use in regimens without dose titration and methods for treatment of patients in need of testosterone replacement therapy. Also disclosed are criteria for continuation and discontinuation of such regimens, based on single serum T concentration levels measured at a steady state at predetermined times after initiation of said regimen and at a predetermined number of hours after administration of a morning dose of the regimen.

Abstract: Apparatus for deflection of a beam of light includes a case, which is configured to be positioned in a path of the beam, and a liquid, which is contained within the case. An array of plates is disposed across a surface of the liquid. The plates are configured to rotate on the surface about respective axes, which are mutually parallel and are spaced apart by a predefined pitch. An actuator is configured to drive a rotation of the plates about the respective axes so as deflect the beam that is incident on the plates.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: Systems, apparatuses, and methods for controlling bandwidth through shared transaction limits are described. An apparatus includes at least a plurality of agents, a plurality of transaction-limit (T-Limit) nodes, a T-Limit manager, and one or more endpoints. The T-Limit manager creates a plurality of credits for the plurality of agents to send transactions to a given endpoint. Then, the T-Limit manager partitions the credits into N+1 portions for N agents, wherein the extra N+1 portion is a shared pool for use by agents when they run out of their private credits. The T-Limit manager assigns a separate private portion of the N portions to the N agents for use by only the corresponding agent. When an agent runs out of private credits, the agent's T-Limit node sends a request to the T-Limit manager for credits from the shared pool.

Abstract: Disclosed are bioavailable solid state (17-?)-3-Oxoandrost-4-en-17-yl dodecanoate compositions and methods of use in administration to mammals in need of thereof. The (17-?)-3-Oxoandrost-4-en-17-yl dodecanoate is preferably provided in a solid state crystalline form having a plurality of peaks corresponding to the peaks shown in FIG. 2, a plurality of crystallites ranging in size from about 40 nm to about 60 nm based as identified via powder x-ray diffraction spectra, and a melting point in the range of about 51° C. to about 63° C. The compositions may be provided in oral or injectable administration form for the treatment of conditions such as in need of testosterone therapy.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one.

Abstract: An optical component includes a substrate and a piezoelectric film formed on the substrate and configured to deform in response to an actuation voltage applied thereto into a pattern of peaks and troughs configured to deflect optical radiation that is incident thereon. The pattern has an amplitude determined by the actuation voltage.

Abstract: The present disclosure is drawn to a methods of treating viral infections using androgen receptor agonists and compositions and dosages suitable therefor.

Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Abstract: A system and method for efficiently arbitrating traffic on a bus. A computing system includes a fabric for routing traffic among one or more agents and one or more endpoints. The fabric includes multiple arbiters in an arbitration hierarchy. Arbiters store traffic in buffers with each buffer associated with a particular traffic type and a source of the traffic. Arbiters maintain a respective urgency counter for keeping track of a period of time traffic of a particular type is blocked by upstream arbiters. When the block is removed, the traffic of the particular type has priority for selection based on the urgency counter. When arbiters receive feedback from downstream arbiters or sources, the arbiters adjust selection priority accordingly. For example, changes in bandwidth requirement, low latency tolerance and active status cause adjustments in selection priority of stored requests.

Abstract: Systems, apparatuses, and methods for controlling bandwidth through shared transaction limits are described. An apparatus includes at least a plurality of agents, a plurality of transaction-limit (T-Limit) nodes, a T-Limit manager, and one or more endpoints. The T-Limit manager creates a plurality of credits for the plurality of agents to send transactions to a given endpoint. Then, the T-Limit manager partitions the credits into N+1 portions for N agents, wherein the extra N+1 portion is a shared pool for use by agents when they run out of their private credits. The T-Limit manager assigns a separate private portion of the N portions to the N agents for use by only the corresponding agent. When an agent runs out of private credits, the agent's T-Limit node sends a request to the T-Limit manager for credits from the shared pool.

Abstract: A system and method for efficiently arbitrating traffic on a bus. A computing system includes a fabric for routing traffic among one or more agents and one or more endpoints. The fabric includes multiple arbiters in an arbitration hierarchy. Arbiters store traffic in buffers with each buffer associated with a particular traffic type and a source of the traffic. Arbiters maintain a respective urgency counter for keeping track of a period of time traffic of a particular type is blocked by upstream arbiters. When the block is removed, the traffic of the particular type has priority for selection based on the urgency counter. When arbiters receive feedback from downstream arbiters or sources, the arbiters adjust selection priority accordingly. For example, changes in bandwidth requirement, low latency tolerance and active status cause adjustments in selection priority of stored requests.

Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.